Full-Time

Key Accounts Manager

Confirmed live in the last 24 hours

AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

No salary listed

Senior

Noida, Uttar Pradesh, India

Category
Strategic Account Management
Sales & Account Management
Required Skills
Sales
Requirements
  • University Science graduate, ideally MBA from reputable institute.
  • Proficient in oral and written communication (English).
  • Must have 5+ years of sales experience with Pharma sector in oncology
  • Should have been a high performer in sales, Cross functional engagement, strong business acumen.
  • Organizational skills, good analytical skills / mind set, ability to manage complexity with a high degree of maturity.
Responsibilities
  • Successfully complete all training requirements, including product examinations.
  • Engage Oncology healthcare professionals in dialogue about approved indications and product efficacy/safety profiles to support on-label prescribing for appropriate patients.
  • Work with Sales Manager to develop a local strategy and business plan to meet or exceed sales and call execution goals in territory.
  • Drive sales performance and ensure sales forecasts and assigned budgets meet or exceed therapeutic and territory expectations.
  • Develop and maintain in-depth knowledge of market, demographic, and managed markets information relative to assigned sales territory.
  • Comply with all regulations regarding interactions with healthcare professionals, distribution of samples, etc.

AstraZeneca focuses on discovering, developing, and selling prescription medicines, primarily in three areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Their products are developed through extensive research and development, which includes rigorous clinical trials and regulatory approvals before reaching the market. AstraZeneca differentiates itself from competitors by investing heavily in scientific research and fostering collaborations through initiatives like their Open Innovation program, which shares resources with the scientific community to speed up drug discovery. The company's goal is to advance healthcare by creating effective treatments for serious diseases and expanding their product offerings through strategic partnerships.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery complements AstraZeneca's R&D efforts.
  • Real-world evidence enhances AstraZeneca's clinical trial processes.
  • Personalized medicine aligns with AstraZeneca's focus on precision medicine.

What critics are saying

  • AI bias in healthcare tools may affect AstraZeneca's AI initiatives.
  • Regulatory challenges could hinder AstraZeneca's production facility expansions.
  • Competition in oncology market poses a threat to AstraZeneca's market share.

What makes AstraZeneca unique

  • AstraZeneca excels in oncology, cardiovascular, and respiratory therapeutic areas.
  • The A.Catalyst Network fosters global collaboration and innovation in healthcare.
  • Open Innovation program accelerates drug discovery through shared resources and partnerships.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

Our Health Needs
Apr 11th, 2025
Study: Racial, ethnic minorities are underrepresented in AI mammogram interpretation

In 2024, AI biotech company Owkin partnered with pharma giant AstraZeneca to develop an AI-powered tool designed to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides.

Medical Update Online
Apr 11th, 2025
AstraZeneca showcases progress in immunisation and real-world evidence addressing global infectious disease burden at ESCMID Global 2025

AstraZeneca showcases progress in immunisation and real-world evidence addressing global infectious disease burden at ESCMID Global 2025.

Cision
Apr 11th, 2025
Result Of Agm

11 April 2025Results of Annual General Meeting held on 11 April 2025AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 9 - 12 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.Resolution. Votes for. % of votes cast

Europawire
Apr 8th, 2025
AstraZeneca Unveils Breakthrough Data on Vaccines and Antibody Therapies for Infections

AstraZeneca unveils breakthrough data on vaccines and antibody therapies for infections.

Delcade
Apr 4th, 2025
Foreign investment in France: Key trends, legal considerations (2024)

AstraZeneca invested €365 million in expanding its production lines in Dunkirk.